Panel: Embedding early-stage treatment pathways

Panel: Embedding early-stage treatment pathways

Wednesday, March 13, 2024 1:20 PM to 2:00 PM · 40 min. (Europe/London)

Information

• Successful implementation of workflow-embedded clinical pathways

• Developing treatments in conjunction with multi-disciplinary teams (including primary care)

• Ensuring commissioning aligns with early-stage treatments

• How can we optimise across the cancer pathway to unlock improvements in care and outcomes?

• Developing innovative partnerships and new ways of working to reduce variations in care

• MDT collaboration to embed timely treatment pathways

Moderator: Ben Clover

Panellists:

Helen Winter, Consultant, University Hospitals Bristol & Weston NHS FT & Clinical Director, Somerset, Wiltshire, Avon & Gloucestershire (SWAG) Cancer Alliance

Raj Jena, Group Leader, CRUK RadNet Cambridge Data Science Team, Dept of Oncology, University of Cambridge & Chair, NIHR Oncology Translational Research Collaboration

Rachel Houlding, National Oncology Healthcare Director, MSD


MSDMSDAt MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, LinkedIn, Instagram, YouTube and Facebook.

Log in

See all the content and easy-to-use features by logging in or registering!